SHPH
Shuttle Pharmaceuticals Holdings, Inc. NASDAQ Listed Aug 31, 2022$4.17
+5.57%
vs $3.95
Mkt Cap $2.4M
52w Low $2.58
1.5% of range
52w High $112.50
50d MA $3.66
200d MA $8.37
P/E (TTM)
—
EV/EBITDA
—
P/B
10.3x
Debt/Equity
0.0x
ROE
-519.9%
P/FCF
-2.5x
RSI (14)
63.00
ATR (14)
$0.35
Beta
0.72
50d MA
$3.66
200d MA
$8.37
Avg Volume
46.3K
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
401 PROFESSIONAL DRIVE · GAITHERSBURG, MD 20879 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | AMC | — | -1.29 | — | 0.67 | -0.0% | +12.9% | -1.8% | -0.0% | +0.7% | -3.3% | — |
| Nov 13, 2025 | AMC | — | -1.05 | — | 2.31 | -0.4% | +0.4% | -17.2% | +9.9% | -6.2% | -7.6% | — |
| Aug 12, 2025 | AMC | — | -3.29 | — | 3.59 | -1.4% | -1.4% | -1.1% | -5.1% | -1.2% | -4.3% | — |
| May 8, 2025 | AMC | — | -7.50 | — | 6.75 | +64.1% | -13.9% | -0.2% | -10.3% | +12.1% | -4.6% | — |
| Mar 20, 2025 | AMC | — | -0.80 | — | 10.14 | +5.0% | +3.8% | -6.3% | -3.4% | +6.0% | -2.3% | — |
| Nov 13, 2024 | AMC | — | -39.75 | — | 27.75 | -2.7% | -3.6% | -6.8% | -6.6% | -4.3% | +0.8% | — |
| Sep 3, 2024 | AMC | — | -24.00 | — | 54.25 | -27.6% | +9.2% | -8.4% | -24.9% | -11.7% | +0.7% | — |
| May 13, 2024 | AMC | — | -20.00 | — | 80.00 | +2.5% | +3.4% | -0.3% | +0.0% | -3.0% | +3.8% | — |
| Mar 21, 2024 | AMC | — | -20.00 | — | 90.50 | -0.6% | -1.1% | -4.2% | -0.9% | -1.2% | -3.3% | — |
| Nov 13, 2023 | AMC | — | -0.11 | — | 100.50 | +1.0% | -0.5% | +2.0% | +1.0% | -5.8% | +3.1% | — |
| Aug 14, 2023 | AMC | — | -0.15 | — | 174.00 | -1.7% | -5.7% | -3.7% | -1.3% | -3.5% | +1.0% | — |
| May 25, 2023 | AMC | — | 0.02 | — | 238.00 | +21.0% | +0.8% | -9.2% | +1.9% | -0.1% | -3.2% | — |
No analyst ratings available.
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | HRT FINANCIAL LP10% | — | Sell | 82,116 | $4.48 | $368K | — | -2.74% | -8.66% |
| Jul 13, 2026 | HRT FINANCIAL LP10% | — | Sell | 1,033 | $4.67 | $5K | 60,238 | -2.74% | -8.66% |
| Jul 10, 2026 | HRT FINANCIAL LP10% | — | Buy | 731 | $3.11 | $2K | 61,271 | +40.54% | -4.11% |
| Jul 9, 2026 | HRT FINANCIAL LP10% | — | Buy | 8,266 | $3.38 | $28K | 60,540 | +40.54% | -4.11% |
| Jul 8, 2026 | HRT FINANCIAL LP10% | — | Sell | 18,531 | $3.52 | $65K | 52,274 | -10.98% | -2.74% |
| Jul 7, 2026 | HRT FINANCIAL LP10% | — | Sell | 10,580 | $3.33 | $35K | 70,805 | -10.98% | -2.74% |
| Jul 6, 2026 | HRT FINANCIAL LP10% | — | Sell | 9,022 | $3.51 | $32K | 81,385 | +9.51% | +40.54% |
| Jul 2, 2026 | HRT FINANCIAL LP10% | — | Buy | 7,851 | $3.54 | $28K | 90,407 | +9.51% | +40.54% |
| Jul 1, 2026 | HRT FINANCIAL LP10% | — | Buy | 3,959 | $3.30 | $13K | 82,556 | -2.23% | -10.98% |
| Jun 30, 2026 | HRT FINANCIAL LP10% | — | Buy | 6,755 | $3.23 | $22K | 78,597 | +5.29% | -8.12% |
| Jun 29, 2026 | HRT FINANCIAL LP10% | — | Buy | 25,836 | $3.44 | $89K | 71,842 | +5.29% | -8.12% |
8-K · 3.02
!! High
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K 3.02: Unregistered Securities Offering
Sep 16
8-K
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K Filing
Sep 11
8-K
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K Filing
Sep 2
8-K · 1.01
!! High
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K 1.01: Material Agreement
Sep 1
8-K · 7.01
! Medium
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 28
NT 10-Q
!! High
Shuttle Pharmaceuticals Holdings, Inc. -- Late Quarterly Report -- Distress Signal
Aug 17
8-K · 8.01
!! High
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 1
8-K · 5.03
! Medium
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jun 11
8-K
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K Filing
May 27
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Governance / Corporate
Lock-up agreements restrict insider selling post-IPO, signaling management confidence in long-term value but limiting share supply, which could support the stock price initially before restrictions expire.
Mar 10
8-K
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K Filing
Shuttle Pharmaceuticals expects 2025 R&D spending of $3.4-3.9 million versus $3.6 million in 2024, signaling a strategic pause as management reassesses its drug development pipeline direction.
Feb 17
8-K · 5.02
!!! Very High
Shuttle Pharmaceuticals Holdings, Inc. -- 8-K 5.02: Executive Change
Shuttle Pharmaceuticals appointed Christopher Cooper as interim co-CEO and engaged his company, Number 2 Capital Corp., as a consultant, signaling potential leadership transitions amid ongoing executive changes.
Feb 2
Institutional (13F) — Top 2
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ubs Group Ag | 5,670 | $4K | Reduced | Mar 2026 |
| 2 | Morgan Stanley | 54 | $98 | — | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 18,789 | $19K | Feb 2026 |
| 2 | Fidelity Nasdaq Composite Index Fund | 264 | $264 | Feb 2026 |
Valuation
Market Cap
$2.4M
Enterprise Value
$23.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
10.34x
P/S
—
P/FCF
-2.46x
EV/EBITDA
—
Shares Out
5.6M
Financials (TTM)
Revenue
$0
Net Income
-$10.3M
EBITDA
-$8.8M
Free Cash Flow
-$9.5M
Op Cash Flow
-$9.5M
EPS Basic
$-7.16
EPS Diluted
$-30.80
EPS Forward
—
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$10.5M
Total Liab.
$8.2M
Total Equity
$2.3M
Cash
$334K
LT Debt
$91K
Book Value/Sh
$0.40
Debt/Equity
0.04x
Current Ratio
0.06
Quick Ratio
0.06
Returns & Growth
ROE
-519.9%
ROA
-111.9%
ROIC
-460.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
+99.2%
Price Returns
2W
+29.9%
1M
+19.8%
3M
+19.1%
6M
-44.0%
12M
-90.7%
Technicals
52W High
$112.50
52W Low
$2.58
50d MA
$3.66
200d MA
$8.37
RSI (14)
63.00
ATR (14)
$0.35
Beta
0.72
Avg Volume
46K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 1:12am
· Source: financialmodelingprep.com